

Briefing document

24 UUR LIVE - Sportpaleis Antwerpen (12-13/03/2021), a Les Flamands, Live Nation and Sportpaleis Groep Initiative.

Roche Diagnostics Belgium is supporting this event without audience, by organising the testing of all participants (artists, crew members, ...) with a Rapid Antigen Test for COVID-19. This Rapid Test will be carried out by healthcare professionals of ZNA, the result of this test will be decisive to enter or not enter the event. Additionally, the participants can volunteer for a self-test under supervision of a healthcare professional. The user experience (from the health care professional & self-testing), the process flow, the app used for result communication and feasibility of both approaches (HCP & self-testing) will be evaluated. Outcomes will be applied in a broader test event later this year.

1. Roche is deeply committed to supporting the global response to the COVID-19 pandemic and understands the importance of timely availability and **fast access to reliable, high quality tests**, which are essential for healthcare systems and patients alike.
2. We are convinced that besides the distance rules and vaccinations, Antigen self-tests, in addition to PCR tests and Rapid Antigen tests for professional use can represent another important building block for combating the pandemic.
3. Rapid Antigen (self) testing is
 - an important part of a “transition strategy”, as a means of safely organizing high attendance meetings (events) in anticipation of group immunity;
 - one of the answers to the increasing pressure from society to allow activities under certain conditions, so that people can meet again indoors;
 - almost a “universal” approach, proposed by experts worldwide as part of the “exit strategy”.
4. During this 24h event, Rapid Tests are used, in addition to other measures, to allow the event to proceed in safe conditions. The workflow is validated with the use of the NAVIFY® Pass and the user experience of the self-test is evaluated in order to gain more insights if these tests are used more often.
5. During this 24h event we will evaluate the test method and result communication using proven qualitative Rapid Tests meaning:
 - getting a quick result (result is ready in 15 minutes, read out window of the result is between 15-30 minutes)
 - no instrument required, allowing decentralized testing or access to testing in areas where laboratory testing is not available
 - sample taking; test method & result communication is based on
 - ✓ Nasopharyngeal testing (cf. video: <https://diagnostics.roche.com/>)
 - ✓ Nasal (self) testing (cf. video: <https://diagnostics.roche.com/>)

✓ NAVIFY® pass



- The organization of a larger test event in a study context will be considered later this year.
- Qualitative means: a good Antigen Test needs to offer a (relatively) high level of sensitivity to not miss infected patients; while at the same time maintaining an acceptable level of specificity to not wrongly diagnose patients (e.g., indicating a SARS-CoV-2 infection while there is none).
The Rapid Antigen Nasopharyngeal test was found to have an overall relative sensitivity of 95.5 % and an overall relative specificity of 99.2%.
The Rapid Antigen Test Nasal has a relative sensitivity of 90.6 % (Ct value \leq 30; 95 % CI: 75.0 % - 98.0 %) for professionally collected samples, and 84.4 % (Ct value \leq 30; 95 % CI: 67.2 % - 94.7 %) for self-collected samples.
- The Roche SARS-CoV-2 Antigen Rapid test, produced by SD Biosensor, was developed in compliance with the strictest quality standards and has been extensively validated by independent bodies. Since the test was launched in September 2020, we have continuously reviewed the rapid antigen test in various patient populations and environments.

For more information please contact:

Roche Diagnostics Belgium

Greenhouse BXL

Berkenlaan 8A

1831 Diegem

vilvoorde.reputationmanagement.roche.com